Payment overview · 2025
General Payments
$966.76
49 reported records · 23 companies
Healthcare provider profile · identity verified
Kenneth C Bingener, DO
Allopathic & Osteopathic Physicians|Family Medicine · BOYERTOWN, PA · NPI 1841266657
Verified facts
What the public records show
CMS Open Payments records show Kenneth C Bingener, DO received $966.76 in general payments during 2025 across 49 reported records.
Novo Nordisk Inc accounted for 19.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $192.77 | 19.9% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $88.56 | 9.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $71.37 | 7.4% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $66.47 | 6.9% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $56.98 | 5.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $56.52 | 5.8% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $55.41 | 5.7% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $43.88 | 4.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.78 | 3.9% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $34.23 | 3.5% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $28.76 | 3.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $27.08 | 2.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $23.80 | 2.5% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $21.58 | 2.2% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.45 | 2.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.09 | 2.1% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $19.98 | 2.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.31 | 2.0% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $19.07 | 2.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.27 | 1.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.61 | 1.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.63 | 1.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.16 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $966.76 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $165.18 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $115.60 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $76.41 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $72.88 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $55.50 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $45.47 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $45.47 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $43.88 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $39.78 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $37.40 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.54 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.54 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $34.23 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $34.23 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.59 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $28.76 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.59 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $27.08 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $21.58 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $20.45 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.12 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $14.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 186 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 54 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 91 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
91 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
186 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 955 | 242 |
| Amlodipine Besylate | Amlodipine Besylate | 792 | 192 |
| Lisinopril | Lisinopril | 667 | 165 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 519 | 134 |
| Levothyroxine Sodium | Levothyroxine Sodium | 459 | 106 |
| Losartan Potassium | Losartan Potassium | 406 | 103 |
| Hydrochlorothiazide | Hydrochlorothiazide | 346 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 342 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 288 | 83 |
| Omeprazole | Omeprazole | 287 | 72 |
| Simvastatin | Simvastatin | 286 | 76 |
| Metformin Hcl Er | Metformin Hcl | 259 | 65 |
| Furosemide | Furosemide | 215 | 64 |
| Eliquis | Apixaban | 186 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 185 | 40 |
| Metformin Hcl | Metformin Hcl | 184 | 44 |
| Gabapentin | Gabapentin | 178 | 49 |
| Allopurinol | Allopurinol | 168 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 168 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 142 | 38 |
| Valsartan | Valsartan | 142 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 133 | 20 |
| Tramadol Hcl | Tramadol Hcl | 132 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 25 |
| Famotidine | Famotidine | 124 | 37 |
| Alprazolam | Alprazolam | 120 | 29 |
| Carvedilol | Carvedilol | 115 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 30 |
| Sertraline Hcl | Sertraline Hcl | 98 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 96 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 20 |
| Kerendia | Finerenone | 91 | 12 |
| Atenolol | Atenolol | 90 | 19 |
| Potassium Chloride | Potassium Chloride | 86 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 26 |
| Montelukast Sodium | Montelukast Sodium | 85 | 24 |
| Meloxicam | Meloxicam | 84 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 29 |
| Lorazepam | Lorazepam | 73 | 18 |
| Trazodone Hcl | Trazodone Hcl | 72 | 16 |
| Enalapril Maleate | Enalapril Maleate | 68 | 18 |
| Glimepiride | Glimepiride | 66 | 18 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 64 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 14 |
| Warfarin Sodium | Warfarin Sodium | 60 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 58 | 13 |
| Ezetimibe | Ezetimibe | 55 | 16 |
| Jardiance | Empagliflozin | 54 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 52 | 16 |
| Farxiga | Dapagliflozin Propanediol | 51 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 49 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | suppressed |
| Irbesartan | Irbesartan | 44 | 12 |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Novolog Flexpen | Insulin Aspart | 42 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | suppressed |
| Ozempic | Semaglutide | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 39 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 38 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 38 | suppressed |
| Celecoxib | Celecoxib | 38 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 23 |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 17 |
| Ipratropium Bromide | Ipratropium Bromide | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 25 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 28 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Diazepam | Diazepam | 24 | 11 |
| Nystatin | Nystatin | 24 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Klor-Con M10 | Potassium Chloride | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 12 |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Cefdinir | Cefdinir | 19 | 17 |
| Cephalexin | Cephalexin | 19 | 15 |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 16 |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Klayesta | Nystatin | 16 | suppressed |
| Nabumetone | Nabumetone | 16 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $966.76 · 49 records | Novo Nordisk Inc | AFREZZA, AIRSUPRA, AREXVY, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE, GARDASIL 9, GEMTESA, INSPIRE, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NP Thyroid 60, NURTEC ODT, ONPATTRO, OTEZLA, Omnipod, Ozempic, PAXLOVID, REPATHA, REXULTI, Rybelsus, SHINGRIX, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error